OncoMatch/Clinical Trials/NCT06810778
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Is NCT06810778 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Duvelisib and Venetoclax for t-cell-prolymphocytic leukemia.
Treatment: Duvelisib · Venetoclax — This is an open-label, phase I/II study of duvelisib in combination with Venetoclax for patients with relapsed/refractory NHL. Duvelisib is an FDA approved, marketed product used to treat certain patients with leukemia and lymphoma and Venetoclax, which is approved for treatment of certain patients with acute myeloid leukemia. The combination of these two drugs is experimental. Experimental means that it is not approved by the United States Food and Drug Administration (FDA). The researchers want to find out how safe it is to combine these drugs and how well this combination can work for your cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: venetoclax (venetoclax)
Previous treatment with venetoclax or a PI3K inhibitor.
Cannot have received: PI3K inhibitor
Previous treatment with venetoclax or a PI3K inhibitor.
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1500 cells/mm3 (1.5 x 10^9/L) or ≥ 1000 cells/mm3 (1.5 x 10^9/L) with bone marrow involvement. Growth factor use is allowed in order to achieve this. Platelet count ≥ 50,000 cells/mm3 (50 x 10^9/L) independent of transfusion within 7 days of screening. Hemoglobin ≥8 g/dL (without transfusion support.)
Kidney function
Creatinine clearance ≥ 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection
Liver function
Serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x upper limit of normal (ULN), bilirubin ≤ 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)
Adequate hepatic function defined as: Serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x upper limit of normal (ULN), bilirubin ≤ 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin). Adequate renal function as defined by: Creatinine clearance ≥ 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection. Patients must meet the following hematologic criteria at screening, unless they have significant bone marrow involvement confirmed on biopsy: Absolute neutrophil count ≥ 1500 cells/mm3 (1.5 x 10^9/L) or ≥ 1000 cells/mm3 (1.5 x 10^9/L) with bone marrow involvement. Growth factor use is allowed in order to achieve this. Platelet count ≥ 50,000 cells/mm3 (50 x 10^9/L) independent of transfusion within 7 days of screening. Hemoglobin ≥8 g/dL (without transfusion support.)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- David Geffen School of Medicine at the University of California at Los Angeles · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify